Gross Profit Analysis: Comparing Viatris Inc. and Taro Pharmaceutical Industries Ltd.

Pharma Giants' Profit Battle: Viatris vs. Taro

__timestampTaro Pharmaceutical Industries Ltd.Viatris Inc.
Wednesday, January 1, 20145800060003669400000
Thursday, January 1, 20156765850004382200000
Friday, January 1, 20167789660004998500000
Sunday, January 1, 20176712510004976200000
Monday, January 1, 20184635080004572000000
Tuesday, January 1, 20194457240004444200000
Wednesday, January 1, 20203997250003796700000
Friday, January 1, 20212966560005575500000
Saturday, January 1, 20222931220006497000000
Sunday, January 1, 20232683230006438600000
Monday, January 1, 2024304979000
Loading chart...

Igniting the spark of knowledge

Gross Profit Trends: Viatris Inc. vs. Taro Pharmaceutical Industries Ltd.

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis compares the gross profit trends of Viatris Inc. and Taro Pharmaceutical Industries Ltd. from 2014 to 2023. Viatris Inc. consistently outperformed Taro, with gross profits peaking at approximately $6.5 billion in 2022, a remarkable 77% increase from 2014. In contrast, Taro's gross profit saw a decline, dropping by 54% over the same period, from a high of $779 million in 2016 to $268 million in 2023. Notably, Viatris experienced a significant surge in 2021, with a 47% increase from the previous year, while Taro's profits continued to dwindle. The data for 2024 is incomplete, highlighting the need for ongoing analysis. This comparison underscores the dynamic nature of the pharmaceutical sector and the importance of strategic financial management.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025